Provided by Tiger Trade Technology Pte. Ltd.

Theravance Biopharma

17.03
0.0000
Volume:- -
Turnover:- -
Market Cap:882.64M
PE:16.30
High:17.03
Open:17.03
Low:17.03
Close:17.03
52wk High:21.03
52wk Low:13.08
Shares:51.83M
Float Shares:25.86M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.05
EPS(LYR):2.06
ROE:20.91%
ROA:1.33%
PB:3.05
PE(LYR):8.27

Loading ...

Zymeworks is Discussing Paying $17 Per Share for Theravance- Bloomberg News

THOMSON REUTERS
·
Jun 29

Theravance Biopharma announces leadership changes amid restructuring

TIPRANKS
·
Jun 24

Theravance Biopharma SVP Áine Miller to exit in November amid restructuring

Reuters
·
Jun 24

Theravance Biopharma SVP Rhonda Farnum sells 13,314 common shares for $218,073.89

Reuters
·
Jun 18

Theravance Biopharma Shareholders Back Directors and Governance Plans

TIPRANKS
·
Jun 13

Theravance Biopharma shareholders elect directors at annual meeting

Reuters
·
Jun 13

Theravance Biopharma: Solid 1Q26 Execution, Cost Cuts, and YUPELRI Momentum Drive Buy Rating and Price Target Increase to $19

TIPRANKS
·
May 28

Theravance Biopharma reports Q1 EPS (10c) vs. (17c) last year

TIPRANKS
·
May 08

Theravance Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Ireland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth

Reuters
·
May 07

Theravance Biopharma Q1 net loss narrows to $4.93 million; revenue rises 15% to $17.7 million

Reuters
·
May 07

Theravance Biopharma Inc: Restructuring Is Expected to Impact About 50% of the Overall Workforce

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc: Full Run-Rate Cost Savings of About$70 Mln Expected to Fully Materialize in Q3

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc: Expects to Incur About $5 to $7 Million in One-Time Cash Severance Costs Related to Restructuring Actions

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc: Restructuring Will Involve Winding Down R&D Function and Significantly Reducing G&a Function

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc - Strategic Review Committee Actively Evaluating Opportunities to Maximize Shareholder Value

THOMSON REUTERS
·
May 07

Theravance Biopharma Q1 Net Income USD -4.933 Million

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc: Implementing an Organizational Restructuring to Streamline Costs and Align Its Resources

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc: Restructuring Is Expected to Reduce Operating Expenses by About 60%

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc: Restructuring Actions Expected to Be Implemented Over Next 2 Quarters

THOMSON REUTERS
·
May 07